Abstract: An orthesis with a foot part and a lower leg part connected with the foot part is characterized in that the foot part comprises an outer shell connected with the lower leg part and an insole arranged inside the outer shell and forming a negative shape of a foot sole; a method for producing such an orthesis includes generating a sole print of patient foot producing an insole matching the sole print; generating a negative shape forming the foot including the insole and lower leg section to be enclosed by the orthesis; generating a positive shape of the foot and lower leg section to be enclosed by the orthesis by filling the negative shape; generating the lower leg part and the outer shell, using the positive shape and the insole as a mould core; and inserting the insole into the outer shell of the foot part.

Abstract: An orthesis with a foot part and a lower leg part connected with the foot part is characterised in that the foot part comprises an outer shell connected with the lower leg part as well as an insole (1) arranged inside the outer shell and forming a negative shape of a sole of a foot. A method for producing such an orthesis includes at least the following method steps: Generation of a sole print of a foot of a patient; Production of an insole (1) matched to the sole print; Generation of a negative shape forming the foot including the insole (1) as well as the section of the lower leg to be enclosed by the orthesis; Generation of a positive shape of the foot and the section of the lower leg to be enclosed by the orthesis by filling the negative shape; Generation of the lower leg part and the outer shell, using the positive shape and the insole (1) as a mould core; and insertion of the insole (1) into the outer shell of the foot part.

Abstract: The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fc? receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample of a patient; b) subjecting the blood sample to an immunoapheresis; c) administering a therapeutically effective antibody or an Fc? receptor-binding active ingredient to the patient.

Abstract: The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fc? receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample of a patient; b) subjecting the blood sample to an immunoapheresis; c) administering a therapeutically effective antibody or an Fc? receptor-binding active ingredient to the patient.

Abstract: A process for manufacturing an adsorbent for reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma in which a carrier material, which is preferably a copolymer derived from (meth)acrylates and or (meth)acrylic acid amides, is activated by amination, and subsequently undergoes thermal treatment at a temperature of over 100° C. An adsorber for the purpose of reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma may be produced from the adsorbent.

Abstract: An adsorbent for reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma comprises a matrix and synthetic lateral chains that are covalently bonded to the matrix. The lateral synthetic chains are comprised of at least two amino groups in which the N2 atoms are at least 2.6 Å apart within at least one lateral synthetic chain. The matrix exhibits porous, unaggregated, spherical particles in a range of particle sizes from 50 to 250 &mgr;m, which possess an exclusionary threshold of at least 107 Daltons, and they exhibit no peptides or aromatic groups of any kind. The at least two amino groups are preferably separated from one another by 4 to 6 carbon atoms. An adsorber for the purpose of reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma may be produced from the adsorbent.

Abstract: An adsorbent for reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma comprises a matrix and synthetic lateral chains that are covalently bonded to the matrix. The matrix can, in principle, consist of any arbitrary carriers; however, it exhibits, preferably, porous, unaggregated, spherical particles in a range of particle sizes from 50 to 250 &mgr;m, which possess an exclusionary threshold of at least 107 Daltons. The lateral chains possess at least two amino groups whose nitrogen atoms in the chain are at least 2.6 Angstroms removed from one another, and they exhibit no peptides or aromatic groups of any kind. The at least two amino groups are preferably separated from one another by 4 to 6 carbon atoms. An adsorber for the purpose of reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma may be produced from the adsorbent.

Abstract: A process for manufacturing an adsorbent for reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma in which a carrier material, which is preferably a copolymer derived from (meth)acrylates and or (meth)acrylic acid amides, is activated by amination, and subsequently undergoes thermal treatment at a temperature of over 100° C. An adsorber for the purpose of reducing the concentration of fibrinogen and/or fibrin in blood or blood plasma may be produced from the adsorbent.